Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413346 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
A Phase 3 study of Acne Vulgaris, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 490
- Enrollment target
- 20
- Study locations
NCT02413346 is a Phase 3 study of Acne Vulgaris that has completed, run by Almirall, S.A.. The registered enrollment target is 490 participants, above the 268-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (83% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02413346, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 490 participants
- Enrollment target
- 20
- Study locations
Study Summary
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
Conditions Studied
Interventions
- DRUG Sarecycline
Study Locations (20)
Florida
- Actavis Investigational Study Site #226 - Clearwater
- Actavis Investigational Study Site #238 - Jupiter
- Actavis Investigational Study Site #249 - Miami
- Actavis Investigational Study Site #145 - Miami
- Actavis Investigational Study Site #211 - Miramar
- Actavis Investigation Study Site # 140 - North Miami Beach
- Actavis Investigational Study Site #151 - Orange
- Actavis Investigational Study Site #203 - Tampa
California
- Actavis Investigational Study Site #245 - Carlsbad
- Actavis Investigational Study Site #129 - Encino
- Actavis Investigational Study Site #209 - Fremont
- Actavis Investigational Study Site #147 - Sacramento
- Actavis Investigational Study Site #150 - San Diego
- Actavis Investigational Study Site #125 - San Diego
- Actavis Investigational Study Site #204 - San Diego
Colorado
- Actavis Investigational Study Site #222 - Denver
- Actavis Investigational Study Site #148 - Wheat Ridge
Alabama
- Actavis Investigational Study Site #206 - Mobile
Arkansas
- Actavis Investigational Study Site #236 - Hot Springs
Georgia
- Actavis Investigational Study Site #242 - Snellville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2015-03-20 |
| Est. Completion | 2016-08-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02413346
The ClinicalTrials.gov registry entry for NCT02413346 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 268-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (83% higher). The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Sarecycline is the first listed.
NCT02413346 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02413346 about?
NCT02413346 is a clinical study titled "A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris". Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
What is the current status of trial NCT02413346?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 2015-03-20. Estimated completion is 2016-08-26.
What conditions does trial NCT02413346 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02413346?
The interventions under investigation include: Sarecycline (DRUG).
Who is sponsoring clinical trial NCT02413346?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02413346 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
P3 Long Term Safety Study of Once Daily SB204 in Acne
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.